PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

Prostate Cancer Clinical Trial

— MIRROR  

Official title:

A Phase 4 Open-Label Multicenter Study of PYLARIFY® PET/CT or PET/MRI in Men With Newly Diagnosed Favorable Intermediate Risk (FIR) Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06074510
• Other study ID #: PYL4301
• Status: Recruiting
• Phase: Phase 4
• Start date: February 8, 2024
• Est. completion date: January 2026

Study information

• Verified date: April 2024
• Source: Lantheus Medical Imaging
• Contact: Senior Clinical Trial Manager
• Phone: +1(646) 975-2540
• Email: PYL4301studyinfo[@]lantheus.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer.

Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cancer outside of the prostate gland may be asked to undergo additional diagnostic test(s) and/or recommend certain treatment(s) for prostate cancer within 2 to 90 days after the study scan. Participants will be monitored for up to 12 months to collecting information about treatment they receive for prostate cancer and results of regular PSA blood draws if ordered by doctors for up to 12 months after the study scan.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 274
• Est. completion date: January 2026
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have the ability to understand and sign an approved informed consent form (ICF)

2. Patients must have the ability to understand and comply with all protocol requirements

3. Patients must be = 18 years of age

4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

5. Patients with life expectancy of at least 13 months as determined by the investigator

6. Patients must have confirmed favorable intermediate risk (FIR) adenocarcinoma of the prostate per 2023 NCCN guidelines. FIR risk group confirmation includes all the following:

• 1 intermediate risk factor (cT2b-cT2c or ISUP Grade Group 2 or PSA 10-20 ng/mL)

• ISUP Grade Group 1 or 2

• <50% biopsy cores positive (e.g., <6 of 12 cores)

Note: Date of the prostate biopsy should be no sooner that 2 weeks and no later than 3 months prior to PYLARIFY PET imaging

Exclusion Criteria:

1. Patients administered any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1 (PYLARIFY imaging)

2. Previous Prostate cancer treatment including radiation, androgen deprivation therapy, brachytherapy, surgery, prostate ablation, hormonal therapies or investigational therapy

3. Known hypersensitivity to the components of PYLARIFY or its analogs

4. Patients with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or complete the study

5. Patients who have any radiographic evidence of T3, N1 or M1 disease on SOC imaging (if performed)

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Piflufolastat F 18 Intravenous Solution [PYLARIFY]
Participants will receive a single dose of 333 MBq (9 mCi) [296 MBq-370 MBq (8 mCi - 10 mCi)] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing

Locations

Country	Name	City	State
United States	Johns Hopkins University	Baltimore	Maryland
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Cleveland Clinic	Cleveland	Ohio
United States	Hoag Cancer Center	Irvine	California
United States	Tower Urology	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Lantheus Medical Imaging

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection rate	The proportion of participants with prostate cancer in whom PYLARIFY PET detected previously occult intraprostatic ISUP grade =3 lesions as assessed by pathology, or in whom PYLARIFY PET detected the presence of either/or extraprostatic extension, seminal vesicle invasion, regional lymph node involvement, distant metastases, divided by the number of subjects who undergo a PYLARIFY PET scan	Day 1
Secondary	Change in intended patient clinical management	Intended medical management plan before and after PYLARIFY PET imaging	Day 30
Secondary	True detection rate	The percentage of participants with at least one true positive lesion identified on PYLARIFY PET imaging and confirmed by the truth standard. This measure includes patients in whom PYLARIFY PET detected previously occult intraprostatic ISUP grade =3 lesions as confirmed by pathology; or patients in whom PYLARIFY PET detected the presence of either/or extraprostatic extension, seminal vesicle invasion, regional lymph node involvement, distant metastases as assessed by central readers and verified by the standard of truth.	Day 1
Secondary	Correct localization rate	The percentage of participants for whom there is a one-to-one correspondence on the same side between the location of at least one lesion outside of prostate capsule (extraprostatic extension, seminal vesicle invasion, pelvic lymph nodes, extrapelvic lymph nodes, extrapelvic bone or extrapelvic soft tissue lesion(s) identified on PYLARIFY PET/CT or PET/MR and the standard of truth.	up to day 90
Secondary	Positive predictive value of PYLARIFY	The percentage of participants who undergo PYLARIFY PET imaging that identifies a lesion or lesions outside of the prostate capsule and have an established standard of truth. Positive predictive value does not require a one-to-one correspondence by lesion location but requires that the lesion and standard of truth be within the same anatomic region, including prostatic, pelvic, extra-pelvic or distant lesions.	up to day 90
Secondary	Sensitivity of PYLARIFY	Sensitivity at the patient level for patients who undergo prostate surgery for prostate and with pelvic lymph nodes removal.	up to day 90
Secondary	Specificity of PYLARIFY	Specificity at the patient level for patients who undergo prostate surgery for prostate and with pelvic lymph nodes removal.	up to day 90
Secondary	Negative predictive value of PYLARIFY	Negative predictive value at the patient level for patients who undergo prostate surgery for prostate and with pelvic lymph nodes removal.	up to day 90
Secondary	Number of participants with Adverse Events		Day 1